Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$71.36 USD
+1.01 (1.44%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $71.35 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RDY 71.36 +1.01(1.44%)
Will RDY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDY
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Other News for RDY
Dr. Reddy’s Addresses USFDA Inspection Observations
Dr. Reddy’s Responds to Acquisition Rumors
Dr. Reddy’s Credit Rating Reaffirmed at AA+
Dr. Reddy’s Upcoming Investor Conferences
Indian Stocks Suffer Worst Decline in Four Years on Election Results